论文部分内容阅读
本实验测定了66例慢性肾小球肾炎(CGN)患者及30例健康对照组的载脂蛋白A-I(ApoA-I)、载脂蛋白B-100(ApoB-100),并观察了血透(HD)和非血透(ND)患者Apo浓度变化。结果:CGN患者随肾功能下降,ApoA-I、ApoA-I/ApoB-100比值渐降,ApoB-100变化不大。血透对Apo浓度影响不大。结论:CGN尿毒症患者存在明显脂质代谢紊乱,可致动脉粥样硬化及加促肾小球硬化,血透不能改善此因素。应进行降脂治疗。
In this study, we measured apolipoprotein AI (ApoA-I) and apolipoprotein B-100 (ApoB-100) in 66 patients with chronic glomerulonephritis (CGN) and 30 healthy controls and observed the effects of hemodialysis HD) and non-hemodialysis (ND) patients with Apo concentration changes. Results: With the decline of renal function in CGN patients, the ratio of ApoA-I, ApoA-I / ApoB-100 gradually decreased and ApoB-100 changed little. Hemodialysis little effect on Apo concentration. Conclusion: Patients with CGN uremia have obvious lipid metabolism disorder, which can cause atherosclerosis and promote glomerular sclerosis. Hemodialysis can not improve this factor. Should be lipid-lowering treatment.